4D Pharma Files US Registration Statement For ADR Programme

(Alliance News) - 4D Pharma PLC on Thursday said it has filed a registration statement in the US ...

Alliance News 26 November, 2020 | 10:53AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - 4D Pharma PLC on Thursday said it has filed a registration statement in the US and expects to launch a new American depositary receipt programme in connection with its proposed Longevity Acquisition Corp merger.

Shares in 4D Pharma were up 3.6% at 93.40 pence in London in morning trading.

The Leeds-based pharmaceutical company announced plans for its merger with NASDAQ-listed special-purpose acquisition company Longevity Acquisition Corp back in October.

The SPAC's shareholders will hold 13% of the enlarged firm. The deal values 4D Pharma shares at GBP1.10 each, GBP144.5 million altogether.

4D Pharma will launch its ADR programme and apply to admit its ADSs for trading on NASDAQ. These will then, if 4D Pharma shareholders give approval, be offered to Longevity shareholders as consideration under the terms of the merger.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
4d pharma PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures